Shire (NASDAQ:SHPG) had its price target lowered by stock analysts at B. Riley from $201.00 to $181.00 in a research report issued on Friday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s target price suggests a potential upside of 35.01% from the stock’s previous close. B. Riley also issued estimates for Shire’s Q1 2018 earnings at $3.75 EPS, Q2 2018 earnings at $3.68 EPS, Q3 2018 earnings at $3.78 EPS, Q4 2018 earnings at $4.07 EPS, FY2019 earnings at $17.50 EPS, FY2020 earnings at $19.00 EPS, FY2021 earnings at $20.00 EPS and FY2022 earnings at $21.00 EPS.
A number of other research firms have also weighed in on SHPG. ValuEngine lowered Shire from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered Shire from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. FBR & Co started coverage on Shire in a research note on Thursday, October 19th. They issued a “buy” rating and a $201.00 price objective for the company. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the stock a “buy” rating in a research note on Wednesday. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Shire in a research note on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $209.23.
Shire (SHPG) opened at $134.06 on Friday. The firm has a market capitalization of $40,337.85, a PE ratio of 8.85, a PEG ratio of 0.75 and a beta of 1.41. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.98 and a quick ratio of 0.52. Shire has a one year low of $123.73 and a one year high of $192.15.
Shire (NASDAQ:SHPG) last released its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 earnings per share for the quarter, topping analysts’ consensus estimates of $3.86 by $0.12. The firm had revenue of $4.14 billion during the quarter, compared to analyst estimates of $4.01 billion. Shire had a return on equity of 14.75% and a net margin of 28.17%. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.37 earnings per share. research analysts forecast that Shire will post 15.27 EPS for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Harding Loevner LP boosted its stake in Shire by 18,894.4% during the third quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after buying an additional 126,865,607 shares during the last quarter. Boston Partners raised its position in Shire by 60.9% during the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after purchasing an additional 886,572 shares during the period. Janus Henderson Group PLC raised its position in Shire by 35.3% during the third quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock valued at $266,613,000 after purchasing an additional 454,092 shares during the period. Ameriprise Financial Inc. raised its position in Shire by 6.4% during the third quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock valued at $245,997,000 after purchasing an additional 96,115 shares during the period. Finally, Third Point LLC purchased a new stake in Shire during the third quarter valued at approximately $183,768,000. 20.74% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/18/shire-shpg-given-new-181-00-price-target-at-b-riley.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.